Periodic Reporting for period 1 - SINSTRO (Unique approach to improving neurological function after stroke with SIN020)
Reporting period: 2019-01-01 to 2019-06-30
Stroke is a sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is lost. Stroke affects 80 million people worldwide and 1 million in Europe per year. It is the second most common cause of death and the leading cause of adult disability. Currently, there are no pharmacological interventions for restoring neurological function after stroke; rehabilitation is the only available treatment option but with limited effect. It is imperative for society to address this largely unmet medical need for stroke patients.
The overall objectives of this project were to develop and optimize a business plan that will guide exploitation and commercialization of Sinntaxis’s lead compound that proved effective in improving the recovery of brain function and has enormous potential to the rehabilitation of post-stroke patients that cannot be targeted by current drugs.
The overall objectives of this project were to develop and optimize a business plan that will guide exploitation and commercialization of Sinntaxis’s lead compound that proved effective in improving the recovery of brain function and has enormous potential to the rehabilitation of post-stroke patients that cannot be targeted by current drugs.
Sinntaxis performed the feasibility study, which then will guide the overall company business development strategy. It provided a valuable understanding of the current trends and opportunities on the stroke therapeutic market, targeted users, competitors, and potential partnerships. A work plan for carrying out validation studies that will evaluate the benefit of our product in post-stroke patients was also developed as part of the project.
The feasibility study has confirmed that there is a clear business opportunity to exploit the global stroke therapeutic market and to deliver first-in-class candidate drugs for the recovery of brain function in patients after stroke.
The feasibility study has confirmed that there is a clear business opportunity to exploit the global stroke therapeutic market and to deliver first-in-class candidate drugs for the recovery of brain function in patients after stroke.
This feasibility study has further confirmed the innovative character of Sinntaxis’s approach. The metabotropic glutamate receptor 5 (mGluR5) imposes an inhibitory action on large-scale neuronal networks preventing recovery of lost brain function. Our compound inhibits mGluR5 and changes brain connectivity, thereby alleviating the functional blockade and improving functional recovery. This also allows for the efficacy of other mechanisms of plasticity for example rehabilitation training. We thrive to validate our promising results further and the potential for novel post-stroke therapeutic that will improve the recovery of the brain, decrease healthcare costs and ease financial burden posed on healthcare budgets. The problem of stroke is growing dramatically and Sinntaxis is assured of the significant impact its innovative approach will have on the stroke burden in Europe and worldwide.